Led · Series B · Aug 2026

Blank Street is a six-year-old coffee chain that began as a single coffee cart in Brooklyn and has grown to more than 100 stores, primarily in London and New York. Its core offering centers on coffee and matcha, with sales increasingly concentrated in the afternoon and evening trading windows. The company is repositioning itself as a "daily luxury" brand and is rethinking menu, hospitality, store design and operating flow to serve more dayparts. Management plans to expand on the U.S. west coast into affluent California neighborhoods and broaden menu items to include products such as ice cream. The firm reported strong consumer demand for out-of-home coffee and matcha as tailwinds for growth. Blank Street is backed by investors including General Atlantic, Left Lane Capital, General Catalyst and Tiger Global and is valued at about $650 million after the latest raise.

Participated · Equity · Aug 2026

Avere Therapeutics is advancing AVR-001 (HS-20118), a cyclic peptide IL-23R antagonist designed for once-weekly oral dosing to treat inflammatory diseases including plaque psoriasis, ulcerative colitis, and Crohn's disease. AVR-001 was licensed from Hansoh Pharmaceutical under an exclusive ex-Greater China agreement signed in June 2026 that included $120 million in upfront payments, up to $2.18 billion in development and sales milestones, and mid-single- to low-double-digit royalties. Hansoh generated Phase Ib data in moderate-to-severe plaque psoriasis showing Week 4 and Week 8 PASI and PASI 75 responses comparable on a cross-trial basis to once-daily icotrokinra, and reported a plasma half-life for AVR-001 of approximately 100 hours supporting once-weekly dosing. Avere announced a $500 million private placement (in addition to a $320 million concurrent placement tied to its merger with NextCure) and said the combined $820 million in pre-merger capital should fund the company's operating plan through 2029. The company is merging with NextCure and, upon closing in the second half of 2026, the combined company will trade on Nasdaq as AVRX with Hansoh expected to hold between 30% and 40% of the combined company and to appoint two directors to the board.

Led · Series B · Aug 2026

Expedition Therapeutics is developing next-generation oral small molecule therapies targeting inflammatory and respiratory diseases, with its lead program EXPD-101, a once-daily DPP1 inhibitor, currently in a global Phase 2 trial for COPD. The company reported that EXPD-101 was well tolerated in Phase 1 with no dose-limiting toxicities and showed dose-proportional pharmacokinetics supporting once-daily dosing. The first patient has been dosed in the Phase 2 COPD study, marking the company’s transition into mid-stage clinical development. Expedition combines translational expertise and clinical development experience with a platform for in-licensing global innovation. The recent $115 million Series B financing led by General Atlantic is intended to fund EXPD-101 through Phase 2, expand the company’s pipeline of therapies for inflammatory diseases, and further its research discovery efforts. Expedition is based in San Francisco and has announced board expansion tied to the financing.

Led · Series F · Jul 2026

Founded in 2017 and based in Palo Alto, SambaNova designs and sells AI systems such as the SN40L and the next-generation SN50 for high-performance inference and model serving. The SN40L launched in September 2023 and became available on-premises in November 2023; the SN50 was unveiled in February 2026 and is due to begin shipping to customers in the second half of 2026 with SoftBank as its first deployment partner. SambaNova positions itself as a provider of “premium inference,” claiming the ability to fit multi-trillion-parameter models onto a single rack to run them quickly. The company has commercial wins including JPMorgan Chase, Saudi Aramco, Intel, and other Japanese firms. It has a multi-year partnership with Intel that includes co-developing products and go-to-market efforts, and it says current funding will help scale operations and secure its supply chain to meet strong demand.

Led · Series F · Jun 2026

ICEYE owns and operates a large synthetic aperture radar (SAR) satellite constellation designed to deliver persistent monitoring and change detection anywhere on Earth. Its customers include organisations in defence and intelligence, environmental monitoring, insurance, and emergency management. The company says its capabilities enable fast decision-making and contribute to safety and sovereign intelligence needs. Founded and headquartered in Finland, ICEYE operates globally with over 1,000 employees across multiple countries, including Poland, Spain, the UK, Australia, Japan, the UAE, Greece, and the US. Financially, ICEYE reported scaling revenue, profitability, and cash generation in 2025 and has secured a €300 million 3-year committed revolving credit facility to support growth and provide liquidity; the article also states the company has previously raised over $760 (amount as reported).